Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

MONTREAL, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) announced today that it has entered into a sale-leaseback transaction for its factory and warehousing facility in ...

Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today announced it has been named to G2's 2025 Best ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate ...

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% ...

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...